Spark Therapeutics (ONCE) Getting Somewhat Positive Press Coverage, Analysis Finds

Headlines about Spark Therapeutics (NASDAQ:ONCE) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spark Therapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.2949486033359 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

How to Become a New Pot Stock Millionaire

ONCE has been the topic of a number of recent research reports. ValuEngine upgraded Spark Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday. Mizuho set a $79.00 price target on Spark Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 29th. Credit Suisse Group reissued an “outperform” rating and set a $75.00 price objective (up previously from $61.00) on shares of Spark Therapeutics in a research report on Thursday, March 8th. Raymond James Financial set a $66.00 price target on Spark Therapeutics and gave the company a “buy” rating in a report on Wednesday, February 21st. Finally, BMO Capital Markets set a $64.00 price target on Spark Therapeutics and gave the company a “buy” rating in a report on Wednesday, February 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and seventeen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $70.58.

ONCE stock traded up $2.57 during trading hours on Thursday, reaching $78.51. 567,641 shares of the stock were exchanged, compared to its average volume of 726,560. The stock has a market cap of $2,826.67, a PE ratio of -10.29 and a beta of 2.56. Spark Therapeutics has a 12 month low of $41.06 and a 12 month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.73). The company had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $9.53 million. Spark Therapeutics had a negative return on equity of 59.38% and a negative net margin of 2,100.80%. equities analysts expect that Spark Therapeutics will post -3.33 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Macon Daily and is owned by of Macon Daily. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://macondaily.com/2018/04/12/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-spark-therapeutics-once-share-price-updated-updated-updated.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply